0001910175-25-000003.txt : 20251014 0001910175-25-000003.hdr.sgml : 20251014 20251010174033 ACCESSION NUMBER: 0001910175-25-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251014 DATE AS OF CHANGE: 20251010 EFFECTIVENESS DATE: 20251014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Indapta Therapeutics Inc. CENTRAL INDEX KEY: 0001910175 ORGANIZATION NAME: EIN: 814700988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-560578 FILM NUMBER: 251388852 BUSINESS ADDRESS: STREET 1: 5000 MONTROSE BLVD. CITY: HOUSTON STATE: TX ZIP: 77006 BUSINESS PHONE: 917-282-9768 MAIL ADDRESS: STREET 1: 5000 MONTROSE BLVD. CITY: HOUSTON STATE: TX ZIP: 77006 D 1 primary_doc.xml X0708 D LIVE 0001910175 Indapta Therapeutics Inc. 5000 Gulf Fwy. Building 4 Room 118 Houston TX TEXAS 77023 917-282-9768 DELAWARE None None Corporation true Mark Frohlich 5000 Gulf Fwy. Building 4 Room 118 Houston TX TEXAS 77023 Executive Officer Director Ronald Martell 5000 Gulf Fwy. Building 4 Room 118 Houston TX TEXAS 77023 Director Lori Hu 5000 Gulf Fwy. Building 4 Room 118 Houston TX TEXAS 77023 Director Fabio Pucci 5000 Gulf Fwy. Building 4 Room 118 Houston TX TEXAS 77023 Director Other Technology Decline to Disclose 06b false 2025-09-24 false true true Includes preferred stock issued upon conversion of outstanding notes, common shares issued in exchange for preferred stock and preferred stock issued in exchange for common stock. false 0 51574072 50800176 773896 Total offering amount/sales amounts reflect (i) value of preferred stock issued upon conversion of outstanding notes; (ii) value of common stock issued in an exchange; and (iii) value of preferred stock issued in an exchange. false 46 0 0 0 false Indapta Therapeutics Inc. /s/ Mark Frohlich Mark Frohlich Chief Executive Officer 2025-10-10